6 ms·
> this looks like one narrow niche knowledge base. I am not expert in this domain, but there are probably some other use cases not covered by existing offerings
by radus 3y ago
> this looks like one narrow niche knowledge base. I am not expert in this domain, but there are probably some other use cases not covered by existing offerings.
UniProt is not niche. It contains curated information about all proteins across numerous domains.
- riku_iki 3y agoyes, proteins is a niche in grand scheme of things
- pama 3y agoThe GP was talking about pharma. Proteins are not niche in pharma. Everything else may be niche in that domain, but proteins make up more than 95% of the targets of the pharmaceutical industry.
- dekhn 3y agoand an increasing number of drugs- in the "old days" it was almost entirely small molecules, but they are starting to peter out (both because the low-hanging fruit has already been plucked, and also, small molecules are a usually a terrible way to modulate biological activity in specific ways.
- riku_iki 3y ago> The GP was talking about pharma. post is not about pharma specifically, but about general bio-medical literature, including genes, diseases, symptoms, etc. > proteins make up more than 95% of the targets of the pharmaceutical industry. do you have references to support this? Some google search says it is 280B market out of 1.5T total pharma market: https://www.alliedmarketresearch.com/protein-therapeutics-market https://www.alliedmarketresearch.com/protein-therapeutics-ma... https://www.statista.com/topics/1764/global-pharmaceutical-industry/#topicOverview https://www.statista.com/topics/1764/global-pharmaceutical-i... Also, it is likely important steps how to research and produce protein drugs, but the end target is to cure diseases, so you need lots of additional data about diseases of all types, symptoms, pathways, trials, etc.
- dekhn 3y agoThis isn't a "do you have references" situation. You're wasting folks time. Nearly all drugs target proteins, with a few that target DNA or RNA.
- riku_iki 3y agoYou can just ignore my comments and walk away? To me you just another "internet expert" which I am not sure why should I blindly trust.
- myownpetard 3y agoYour sources are talking about the ratio of small molecule vs. large molecule drugs. Even if you're developing small molecule drugs you are likely targeting some aspect of protein signaling/gene expression. People are being dismissive of your comments because to say that proteins are niche in the context of pharma is like saying advertising is niche in the context of Meta and Google.
- riku_iki 3y ago> People are being dismissive of your comments because to say that proteins are niche in the context of pharma is like saying advertising is niche in the context of Meta and Google. its all about how you define word "niche", for google, main revenue stream is supported by several pillars: search tech, infra tech, ads tech, ecosystem+network effect, human management. You remove one pillar, and everything is destroyed, so one can say ads is one of the niches in their food chain. I suspect with proteins it is about the same. > in the context of pharma there is no context of pharma. Post is about more broad bio-medical publications.
- myownpetard 3y ago> Word of advice to all those who are chomping at the bit to disrupt pharma with AI. Literally the first line in the comment that started this thread.